Achieving clinical and commercial success in the anti-obesity market

24 July 2023

In this week's Expert View, Tobias Handschuh and Clemens Freytag from Oliver Wyman’s health and life sciences division provide insight into the strategic imperatives drugmakers must embrace if they are to compete in the obesity space.

Obesity is one of the most urgent health challenges of our time. With more than half the global population estimated to be either overweight or living with obesity in the next 12 years and the cost of the condition is predicted to soar to $4.3 trillion, there is no question that innovative weight loss solutions will significantly contribute to the sustainability of the healthcare sector.

Having effective therapeutic options for weight has long been one of the most important underserved needs in the obesity space.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK